Structure-based design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity

ACS Chemical Biology

Volumn 3, Issue 5, 2008, Pages 305-316

  Xie, Peng ^a   Williams, Douglas S ^a   Atilla Gokcumen, G Ekin ^a,b   Milk, Leslie ^a   Xiao, Min ^a   Smalley, Keiran S M ^a   Herlyn, Meenhard ^a   Meggers, Eric ^a,b   Marmorstein, Ronen ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 5 (6 QUINOXALINYLMETHYLENE) 2,4 THIAZOLIDINEDIONE; E5E2; MYRICETIN; ORGANOMETALLIC COMPOUND; ORGANORUTHENIUM PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE; RUTHENIUM COMPLEX; STAUROSPORINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; RUTHENIUM;

ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG INHIBITION; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; IC 50; MELANOMA CELL; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; PROTEIN BINDING; SYNTHESIS; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; ORGANOMETALLIC COMPOUNDS; PROTEIN BINDING; RUTHENIUM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 44649150564     PISSN: 15548929     EISSN: None     Source Type: Journal    
DOI: 10.1021/cb800039y     Document Type: Article

References (44)

1. Fruman, D. A., Meyers, R. E., and Cantley, L. C. (1998) Phosphoinositide kinases, Annu. Rev. Biochem. 67, 481-507.
2. Vanhaesebroeck, B., and Waterfield, M. D. (1999) Signaling by distinct classes of phosphoinositide 3-kinases, Exp. Cell Res. 253, 239-254.
3. Domin, J., and Waterfield, M. D. (1997) Using structure to define the function of phosphoinositide 3-kinase family members, FEBS Lett. 410, 91-95.
4. Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., and Downward, J. (1994) Phosphatidylinositol-3-OH kinase as a direct target of Ras, Nature 370, 527-532.
5. Vivanco, I., and Sawyers, C. L. (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer, Nat. Rev. Cancer 2, 489-501.
6. Whitman, M., Kaplan, D. R., Schaffhausen, B., Cantley, L., and Roberts, T. M. (1985) Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation, Nature 315, 239-242.
7. Sugimoto, Y., Whitman, M., Cantley, L. C., and Erikson, R. L. (1984) Evidence that the Rous sarcoma virus transforming gene product phosphorylates phosphatidylinositol and diacylglycerol, Proc. Natl. Acad. Sci. U.S.A. 81, 2117-2121.
8. Samuels, Y., Diaz, L. A., Jr., Schmidt-Kittler, O., Cummins, J. M., Delong, L., Cheong, I., Rago, C., Huso, D. L., Lengauer, C., Kinzler, K. W., Vogelstein, B., and Velculescu, V. E. (2005) Mutant PIK3CA promotes cell growth and invasion of human cancer cells, Cancer Cell 7, 561-573.
9. Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., Willson, J. K., Markowitz, S., Kinzler, K. W., Vogelstein, B., and Velculescu, V. E. (2004) High frequency of mutations of the PIK3CA gene in human cancers, Science 304, 554.
10. Vogt, P. K., Kang, S., Elsliger, M. A., and Gymnopoulos, M. (2007) Cancer-specific mutations in phosphatidylinositol 3-kinase, Trends Biochem. Sci. 32, 342-349.
11. Benistant, C., Chapuis, H., and Roche, S. (2000) A specific function for phosphatidylinositol 3-kinase α (p85α-p110α) in cell survival and for phosphatidylinositol 3-kinase β (p85α-p110β) in de novo DNA synthesis of human colon carcinoma cells, Oncogene 19, 5083-5090.
12. Mizoguchi, M., Nutt, C. L., Mohapatra, G., and Louis, D. N. (2004) Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas, Brain Pathol. 14, 372-377.
13. Hickey, F. B., and Cotter, T. G. (2006) BCR-ABL regulates phosphatidylinositol 3-kinase-p110γ transcription and activation and is required for proliferation and drug resistance, J. Biol. Chem. 281, 2441-2450.
14. Rommel, C., Camps, M., and Ji, H. (2007) PI3Kδ and PI3Kγ: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat. Rev. Immunol. 7, 191-201.
15. Davies, S. P., Reddy, H., Caivano, M., and Cohen, P. (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors, Biochem. J. 351, 95-105.
16. Baggiolini, M., Dewald, B., Schnyder, J., Ruch, W., Cooper, P. H., and Payne, T. G. (1987) Inhibition of the phagocytosis-induced respiratory burst by the fungal metabolite wortmannin and some analogues, Exp. Cell Res. 169, 408-418.
17. Vlahos, C. J., Matter, W. F., Hui, K. Y., and Brown, R. F. (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl- 4H-1-benzopyran-4-one (LY294002), J. Biol. Chem. 269, 5241-5248.
18. Jacobs, M. D., Black, J., Futer, O., Swenson, L., Hare, B., Fleming, M., and Saxena, K. (2005) Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002, J. Biol. Chem. 280, 13728-13734.
19. Knight, Z. A., Chiang, G. G., Alaimo, P. J., Kenski, D. M., Ho, C. B., Coan, K., Abraham, R. T., and Shokat, K. M. (2004) Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold, Bioorg. Med. Chem. 12, 4749-4759.
20. Meggers, E. (2007) Exploring biologically relevant chemical space with metal complexes, Curr. Opin. Chem. Biol. 11, 287-292.
21. Williams, D. S., Carroll, P. J., and Meggers, E. (2007) Platinum complex as a nanomolar protein kinase inhibitor, Inorg. Chem. 46, 2944-2946.
22. Bregman, H., Carroll, P. J., and Meggers, E. (2006) Rapid access to unexplored chemical space by ligand scanning around a ruthenium center: discovery of potent and selective protein kinase inhibitors, J. Am. Chem. Soc. 128, 877-884.
23. Debreczeni, J. E., Bullock, A. N., Atilla, G. E., Williams, D. S., Bregman, H., Knapp, S., and Meggers, E. (2006) Ruthenium half-sandwich complexes bound to protein kinase Pim-1, Angew. Chem., Int. Ed. 45, 1580-1585.
24. Smalley, K. S., Contractor, R., Haass, N. K., Kulp, A. N., Atilla-Gokcumen, G. E., Williams, D. S., Bregman, H., Flaherty, K. T., Soengas, M. S., Meggers, E., and Herlyn, M. (2007) An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells, Cancer Res. 67, 209-217.
25. Atilla-Gokcumen, G. E., Williams, D. S., Bregman, H., Pagano, N., and Meggers, E. (2006) Organometallic compounds with biological activity: a very selective and highly potent cellular inhibitor for glycogen synthase kinase 3, Chembiochem 7, 1443-1450.
26. Williams, D. S., Atilla, G. E., Bregman, H., Arzoumanian, A., Klein, P. S., and Meggers, E. (2005) Switching on a signaling pathway with an organoruthenium complex, Angew. Chem., Int. Ed. 44, 1984-1987.
27. Bregman, H., and Meggers, E. (2006) Ruthenium half-sandwich complexes as protein kinase inhibitors: an N-succinimidyl ester for rapid derivatizations of the cyclopentadienyl moiety, Org. Lett. 8, 5465-5468.
28. Walker, E. H., Pacold, M. E., Perisic, O., Stephens, L., Hawkins, P. T., Wymann, M. P., and Williams, R. L. (2000) Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine, Mol. Cell 6, 909-919.
29. Camps, M., Ruckle, T., Ji, H., Ardissone, V., Rintelen, F., Shaw, J., Ferrandi, C., Chabert, C., Gillieron, C., Francon, B., Martin, T., Gretener, D., Perrin, D., Leroy, D., Vitte, P. A., Hirsch, E., Wymann, M. P., Cirillo, R., Schwarz, M. K., and Rommel, C. (2005) Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis, Nat. Med. 11, 936-943.
30. Knight, Z. A., Gonzalez, B., Feldman, M. E., Zunder, E. R., Goldenberg, D. D., Williams, O., Loewith, R., Stokoe, D., Balla, A., Toth, B., Balla, T., Weiss, W. A., Williams, R. L., and Shokat, K. M. (2006) A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling, Cell 125, 733-747.
31. Bregman, H., Williams, D. S., Atilla, G. E., Carroll, P. J., and Meggers, E. (2004) An organometallic inhibitor for glycogen synthase kinase 3, J. Am. Chem. Soc. 126, 13594-13595.
32. Meggers, E., Atilla-Gokcumen, G. E., Bregman, H., Maksimoska, J., Mulcahy, S. P., Pagano, N., and Williams, D. S. (2007) Exploring chemical space with organometallics: ruthenium complexes as protein kinase inhibitors, Synlett 8, 1177-1189.
33. Smalley, K. S., and Herlyn, M. (2005) Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics, Ann. N.Y. Acad. Sci. 1059, 16-25.
34. Stahl, J. M., Sharma, A., Cheung, M., Zimmerman, M., Cheng, J. Q., Bosenberg, M. W., Kester, M., Sandirasegarane, L., and Robertson, G. P. (2004) Deregulated Akt3 activity promotes development of malignant melanoma, Cancer Res. 64, 7002-7010.
35. Smalley, K. S., Haass, N. K., Brafford, P. A., Lioni, M., Flaherty, K. T., and Herlyn, M. (2006) Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases, Mol. Cancer Ther. 5, 1136-1144.
36. Huang, C. H., Mandelker, D., Schmidt-Kittler, O., Samuels, Y., Velculescu, V. E., Kinzler, K. W., Vogelstein, B., Gabelli, S. B., and Amzel, L. M. (2007) The structure of a human p110α/p85α complex elucidates the effects of oncogenic PI3Kα mutations, Science 318, 1744-1748.
37. Walker, E. H., Perisic, O., Ried, C., Stephens, L., and Williams, R. L. (1999) Structural insights into phosphoinositide 3-kinase catalysis and signalling, Nature 402, 313-320.
38. Collaborative Computational Project, Number 4 (1994) The CCP4 suite: programs for protein crystallography, Acta Crystallogr., Sect. D: Biol. Crystallogr. 50, 760-763.
39. Vagin, A., and Teplyakov, A. (1997) MOLREP: an automated program for molecular replacement, J. Appl. Crystallogr. 30, 1022-1025.
40. Brunger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T., and Warren, G. L. (1998) Crystallography & NMR system: A new software suite for macromolecular structure determination, Acta Crystallogr., Sect. D: Biol. Crystallogr. 54, 905-921.
41. Emsley, P., and Cowtan, K. (2004) Coot: model-building tools for molecular graphics, Acta Crystallogr., Sect. D: Biol. Crystallogr. 60, 2126-2132.
42. Jones, T. A., Zou, J. Y., Cowan, S. W., and Kjeldgaard, M. (1991) Improved methods for building protein models in electron density maps and the location of errors in these models, Acta Crystallogr., Sect. A: Found. Crystallogr. 47, 110-119.
43. Krissinel, E., and Henrick, K. (2004) Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions, Acta Crystallogr., Sect. D: Biol. Crystallogr. 60, 2256-2268.
44. Smalley, K. S. M., Brafford, P., Haass, N. K., Brandner, J. M., Brown, E., and Herlyn, M. (2005) Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion, Am. J. Pathol. 166, 1541-1554.